MARKET

CRIS

CRIS

Curis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.00
-0.40
-4.76%
Closed 17:48 09/24 EDT
OPEN
8.30
PREV CLOSE
8.40
HIGH
8.32
LOW
8.00
VOLUME
883.82K
TURNOVER
--
52 WEEK HIGH
17.40
52 WEEK LOW
1.020
MARKET CAP
732.77M
P/E (TTM)
-17.7699
1D
5D
1M
3M
1Y
5Y
10 Pharmaceutical Stocks to Buy Today According to Tiger Cub Billionaire Lee Ainslie
In this article, we will take a look at 10 pharmaceutical stocks to buy today according to Tiger Cub Billionaire Lee Ainslie. You can skip our detailed analysis of Lee Ainslie’s history, investment strategy, and hedge fund performance, and go directly to s...
Insider Monkey · 6d ago
Curis to Present at Upcoming Healthcare Conferences in September
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in the following upc...
PR Newswire · 09/02 12:00
Colony Family Offices, LLC Buys Dimensional U.S. ...
GuruFocus News · 09/01 22:38
INCR, NCNO, ASMB and FIVE among after hours movers
Gainers: INCR +15.3%. NCNO +6.7%. SMTC +4.9%. NTNX +4.6%. CLXT +2.2%. Losers: ASMB -14.1%. FIVE -9.3%. OMCL -7.7%. SWBI -4.2%. CRIS -3.1%.
Seekingalpha · 09/01 21:35
Nantahala Capital Management, LLC Buys Herman Miller Inc, Silverback Therapeutics Inc, Red ...
GuruFocus News · 08/24 15:38
Return on Capital Employed Overview: Curis
Pulled from Benzinga Pro data Curis (NASDAQ:CRIS) reported Q2 sales of $2.29 million. Earnings fell to a loss of $10.65 million, resulting in a 21.02% decrease from last quarter.
Benzinga · 08/20 17:50
If You Had Bought Curis (NASDAQ:CRIS) Stock A Year Ago, You Could Pocket A 429% Gain Today
It hasn't been the best quarter for Curis, Inc. ( NASDAQ:CRIS ) shareholders, since the share price has fallen 29% in...
Simply Wall St. · 08/06 06:27
Curis (CRIS) Reports Q2 Loss, Lags Revenue Estimates
Curis (CRIS) delivered earnings and revenue surprises of -9.09% and -1.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/03 21:25
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRIS. Analyze the recent business situations of Curis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRIS stock price target is 23.00 with a high estimate of 27.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 153
Institutional Holdings: 85.16M
% Owned: 92.98%
Shares Outstanding: 91.60M
TypeInstitutionsShares
Increased
39
18.48M
New
51
7.03M
Decreased
31
8.93M
Sold Out
42
12.97M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Martyn Greenacre
President/Chief Executive Officer/Director
James Dentzer
Chief Financial Officer
William Steinkrauss
Other
Robert Martell
Independent Director
Kenneth Kaitin
Independent Director
Lori Kunkel
Independent Director
Marc Rubin
No Data
About CRIS
Curis, Inc. is a biotechnology company focused on the development of therapeutics for the treatment of cancer. The Company’s drug candidates include CA-4948 and CI-8993. CA-4948 is an orally available small-molecule inhibitor of Interleukin-I receptor-associated kinase 4, which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. It is also conducting a Phase I open-label, single-arm dose escalating trial in patients with acute myeloid leukemia, and myelodysplastic syndromes. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of the T cell activation signaling pathway. The Company initiated a Phase Ia/Ib trial of CI-8993 in patients with solid tumors. The Company’s products pipeline includes Fimepinostat, CA-170, CA-327, and PD1/TIM3 Program.

Webull offers kinds of Curis, Inc. stock information, including NASDAQ:CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.